Evidence map›Paper›PMID 26751209›Full record

ArticlePloS one2016

Brugia malayi Asparaginyl-tRNA Synthetase Stimulates Endothelial Cell Proliferation, Vasodilation and Angiogenesis.

Jeeva Jothi D, Muthu Dhanraj, Shanmugam Solaiappan, Sanjana Sivanesan, Michael Kron, Anuradha Dhanasekaran

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Pathogens (Basel, Switzerland) · 2024
    Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Jeeva Jothi DCenter for Biotechnology, Anna University, Chennai-25, Tamil Nadu, India.
Muthu DhanrajCenter for Biotechnology, Anna University, Chennai-25, Tamil Nadu, India.
Shanmugam SolaiappanCenter for Biotechnology, Anna University, Chennai-25, Tamil Nadu, India.
Sanjana SivanesanSri Ramachandra Medical College, Porur, Chennai, India.
Michael KronBiotechnology and Bioengineering Center, the Department of Medicine, Division of Infectious Diseases, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America.
Anuradha DhanasekaranCenter for Biotechnology, Anna University, Chennai-25, Tamil Nadu, India.
Anna University, Chennai · INMedical College of Wisconsin · USSri Ramachandra Institute of Higher Education and Research · IN

Funding

Natural products as antifilarial asparaginyl-tRNA synthetase inhibitorsR21AI105472 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI KRON, MICHAEL A., SHEN, BEN · 2013 to 2014
$475k
NIAID NIH HHS R21 AI105472NIAID NIH HHS R21AI105472PHS HHS U01053877
6 · The paper itself

Abstract

A hallmark of chronic infection with lymphatic filarial parasites is the development of lymphatic disease which often results in permanent vasodilation and lymphedema, but all of the mechanisms by which filarial parasites induce pathology are not known. Prior work showed that the asparaginyl-tRNA synthetase (BmAsnRS) of Brugia malayi, an etiological agent of lymphatic filariasis, acts as a physiocrine that binds specifically to interleukin-8 (IL-8) chemokine receptors. Endothelial cells are one of the many cell types that express IL-8 receptors. IL-8 also has been reported previously to induce angiogenesis and vasodilation, however, the effect of BmAsnRS on endothelial cells has not been reported. Therefore, we tested the hypothesis that BmAsnRS might produce physiological changes in endothelial by studying the in vitro effects of BmAsnRS using a human umbilical vein cell line EA.hy926 and six different endothelial cell assays. Our results demonstrated that BmAsnRS produces consistent and statistically significant effects on endothelial cells that are identical to the effects of VEGF, vascular endothelial growth factor. This study supports the idea that new drugs or immunotherapies that counteract the adverse effects of parasite-derived physiocrines may prevent or ameliorate the vascular pathology observed in patients with lymphatic filariasis.

Indexed as

AnimalsAspartate-tRNA LigaseBrugia malayiCell Line, TransformedCell ProliferationChemotaxisChick EmbryoChorioallantoic MembraneEscherichia coliGene ExpressionHelminth ProteinsHost-Parasite InteractionsHumansHuman Umbilical Vein Endothelial CellsNeovascularization, PathologicProtein Bindingasparaginyl-tRNA synthetaseAspartate-tRNA LigaseHelminth ProteinsReceptors, Interleukin-8Recombinant ProteinsRNA, Transfer, Amino AcylVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID26751209
PMCPMC4709172
OpenAlexW2239840732

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.